Table 1.
Baseline characteristics of the study population
| Baseline characteristics | n=61 |
|---|---|
| Males | 44 (72·1) |
| Age, years | 58·0 [47·1-66·1] |
| Retransplantation | 7 (11·5) |
| Time post-transplantation, years | 4·5 [1·8-11·3] |
| Cause of ESKD | |
| Diabetes | 5 (8·2) |
| Vascular | 7 (11·5) |
| Glomerular | 10 (16·4) |
| Polycystic kidney disease | 15 (24·6) |
| Others and unknown | 24 (39·3) |
| Diabetes | 13 (21·3) |
| Obesity (BMI>30kg/m²) | 8 (13·1) |
| Maintenance immunosuppressive therapy | |
| Corticosteroïds | 54 (88·5) |
| Antimetabolites* | 38 (62·3) |
| Calcineurin inhibitors | 57 (93·4) |
| mTOR inhibitors | 6 (9·8) |
| Belatacept | 1 (1·6) |
| Laboratory values | |
| Creatininemia, µmol/L | 145·0 [106·5-180·5] |
| White blood cell count, × 109/l | 6·6 [5·2-8·4] |
| Lymphocytes count, × 109/l | 1·3 [0·8-1·7] |
| Donor-speciifc antibodies | 13 (21·3) |
Data are shown as number and percentage, n (%) or median and interquartile range, m (IQR); ESKD: End-Stage Kidney Disease; BMI: Body Mass Index. * Mycophenolate Mofetil/ Mycophenolic Acid, n=33; Azathioprine, n=5).